Amanati Ali, Karimi Abdollah, Fahimzad Alireza, Shamshiri Ahmad Reza, Fallah Fatemeh, Mahdavi Alireza, Talebian Mahshid
Pediatric Infections Research Center, Shahid Beheshti University of Medical Sciences, Tehran 1551415468, Iran.
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran 1439955991, Iran.
Children (Basel). 2017 Jul 3;4(7):56. doi: 10.3390/children4070056.
Among hospital-acquired infections (HAIs) in children, ventilator-associated pneumonia (VAP) is the most common after blood stream infection (BSI). VAP can prolong length of ventilation and hospitalization, increase mortality rate, and directly change a patient's outcome in Pediatric Intensive Care Units (PICU).
The research on VAP in children is limited, especially in Iran; therefore, the identification of VAP incidence and mortality rate will be important for both clinical and epidemiological implications.
Mechanically ventilated pediatric patients were assessed for development of VAP during hospital course on the basis of clinical, laboratory and imaging criteria. We matched VAP group with control group for assessment of VAP related mortality in the critically ill ventilated children.
VAP developed in 22.9% of critically ill children undergoing mechanical ventilation. Early VAP and late VAP were found in 19.3% and 8.4% of VAP cases, respectively. Among the known VAP risk factors that were investigated, immunodeficiency was significantly greater in the VAP group (p = 0.014). No significant differences were found between the two groups regarding use of corticosteroids, antibiotics, PH (potential of hydrogen) modifying agents (such as ranitidine or pantoprazole), presence of nasogastric tube and total or partial parenteral nutrition administration. A substantial number of patients in the VAP group had more than four risk factors for development of VAP, compared to those without VAP (p = 0.087). Mortality rate was not statistically different between the VAP and control groups (p = 0.477).
VAP is still one of the major causes of mortality in PICUs. It is found that altered immune status is a significant risk factor for acquiring VAP. Also, occurrence of VAP was high in the first week after admission in PICU.
在儿童医院获得性感染(HAIs)中,呼吸机相关性肺炎(VAP)是仅次于血流感染(BSI)的最常见感染。VAP可延长通气时间和住院时间,增加死亡率,并直接改变儿科重症监护病房(PICU)患者的预后。
关于儿童VAP的研究有限,尤其是在伊朗;因此,确定VAP的发病率和死亡率对于临床和流行病学意义都很重要。
根据临床、实验室和影像学标准,对机械通气的儿科患者在住院期间VAP的发生情况进行评估。我们将VAP组与对照组进行匹配,以评估重症通气儿童中与VAP相关的死亡率。
在接受机械通气的重症儿童中,22.9%发生了VAP。早期VAP和晚期VAP分别占VAP病例的19.3%和8.4%。在调查的已知VAP危险因素中,VAP组的免疫缺陷明显更高(p = 0.014)。在使用皮质类固醇、抗生素、pH(酸碱度)调节剂(如雷尼替丁或泮托拉唑)、鼻胃管的存在以及全肠外或部分肠外营养给药方面,两组之间未发现显著差异。与无VAP的患者相比,VAP组中有相当数量的患者具有超过四个VAP发生的危险因素(p = 0.087)。VAP组和对照组之间的死亡率无统计学差异(p = 0.477)。
VAP仍然是PICU中主要的死亡原因之一。发现免疫状态改变是获得VAP的一个重要危险因素。此外,PICU入院后第一周VAP的发生率较高。